Releases - DiaGenic ASA

View:

2009

 

Found press releases

 

FINANCIAL CALENDER FOR 2010

12/21/2009 9:11 AM EST
4th quarter results 2009 and preliminary annual result for 2009: 25 February 2010 1st quarter results 2010: 20 May 2010 Annual General Meeting: 3 June2010 2nd quarter results 2010: 19 August 2010 3rd quarter results 2010: 29 October 2010 This information is subject to disclosure requirements according to §5-12 vphl (Norwegian Securities Trading Act)

EXTRAORDINARY GENERAL MEETING HELD IN DIAGENIC ASA

12/18/2009 6:16 AM EST
The extraordinary general meeting of DiaGenic ASA was held on 18 December 2009.

The general meeting resolved share capital increase by issue of new shares and issue of warrants, in accordance with the proposals set forth in the notice.

The minutes from the extraordinary general meeting will be available at www.newsweb.no and www.diagenic.com.


MD PhD Erik Christensen, Managing Director
Telephone: +47...

Share capital increase

12/7/2009 10:25 AM EST
On 26 November 2009 DiaGenic ASA announced a private placement of 12.5 million new shares at a subscription price of NOK 2.75 per share. The share capital increase has now been registered with the Norwegian Registry of Business Enterprises. Following the registration, DiaGenic’s share capital is NOK 3,336,826, divided into 66,736,520 shares, each with a nominal value of NOK 0.05. The Articles of Association of the...

NOTICE OF EXTRAORDINARY GENERAL MEETING

11/27/2009 9:00 AM EST
The board of directors of DiaGenic ASA (the “Company”) hereby convenes an extraordinary general meeting.

Time: 18 December 2009 at 10:00 hours (CET)
Place: Grenseveien 92, Oslo, Norway


Agenda:

1. Opening of the meeting by chairman of the board Håkon Sæterøy, including the taking of attendance of shareholders present
2. Election of chairman of the meeting and a person to co-sign the minutes
3. Approval of notice...

DISCLOSURE OF SHAREHOLDINGS

11/26/2009 7:25 AM EST
Reference is made to the stock exchange release dated 26 November 2009 regarding completion of a Private Placement, which upon registration will increase the total number of shares from 54,236,520 shares to 66,736,520 shares. Consequently the equity stake will change upon registration of the new shares and the co-founders and primary insiders Erik Anders Lönneborg and Praveen Sharma which triggers disclosure of...

NOTIFICATION OF TRADE AMONG PRIMARY INSIDER

11/26/2009 2:54 AM EST
DiaGenic announced completion of a private placement on 26 November 2009. Mandatory notification of trade of a primary insider of DiaGenic ASA took place in the placing. Håkon Sæterøy, Executive Chairman of the Board of DiaGenic ASA, has received the minimum allotment of 155,000 shares in this placing at NOK 2.75 per share. Sæterøy`s overall exposure in the Company has increased to a total of 1,396,478 shares post...

Financing DiaGenic - Private Placement completed

11/26/2009 2:45 AM EST
Oslo, 26 November 2009: DiaGenic ASA ("DiaGenic"or the "Company" - OSE: DIAG),

With reference to stock exchange release dated 25 November 2009 regarding the contemplated capital increase in the Company (the "Private Placement").

The bookbuilding period has now ended, and the Private Placement was over-subscribed. The Company is pleased to inform that it has resolved to issue 12.5 million shares. The subscription...

Financing DiaGenic ASA

11/25/2009 11:32 AM EST
With reference to the statement in presentation of the 3rd Quarter report 2009 that the Board is working to secure further financing of the Company, DiaGenic and its advisors has now decided to carry out an equity offering through a private placement. The book building will start after the close of Oslo Stock Exchange today.

The new shares will be issued using existing proxies. The new shares will be offered in...

NOTIFICATION OF TRADE AMONG PRIMARY INSIDERS

11/16/2009 8:00 AM EST
On 16 November 2009 mandatory notifications of trade among primary insiders of DiaGenic ASA took place. The primary insiders have settled forward contracts by purchasing 1,245,000 shares. In addition the primary insiders have entered into Total Return equity Swap (TRS) agreements with exposure for 835,000 shares in DiaGenic. Net exposure among the insiders is unchanged by these transactions. The transactions are...

REPORT FOR THIRD QUARTER 2009

10/30/2009 3:00 AM EST
Norwegian Research Council Names DiaGenic “Most Innovative Company of the Year”

The third quarter report for 2009 was approved by the Board of Directors on 29 October 2009. Please find the report and an investor presentation attached.

Highlights from the report:
• Distributor contract for UK and Ireland signed with a world leading provider of diagnostic testing and services
• Minimum sales volumes exceeds 100,000...

DiaGenic ASA

DiaGenic ASA is an innovative Norwegian life sciences company founded in 1998 and listed on the Oslo Stock Exchange.

DiaGenic develops patient-friendly tests for the early diagnosis of devastating diseases where early in...

View more


  CONTACT